Urology Times staff

2121 PARK ST


How appropriate use criteria was created for PSMA-PET imaging

January 20, 2022

“There is a rather extensive process of how to develop appropriate use criteria. It is primarily based on literature and evidence, systematic reviews, and analysis of those data,” says Hossein Jadvar, MD, PhD.

Dr. Lerner on the pivotal OLYMPUS trial of Jelmyto in UTUC

January 20, 2022

“Of the 42 patients who achieved a complete response, 41 of those were evaluable for duration of response, which was the focus of the manuscript that was just published last month,” says Seth P. Lerner, MD.

Presentation: Head-to-Head Comparison of 18F-Fluciclovine and 68Ga-PSMA-11 in Prostate Cancer

January 20, 2022

Drs Steven Finkelstein and Louis J. Mazzarelli highlight data revealed in the article “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Birgit Pernthaler, et al.